NCT03953235: A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

NCT03953235
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: HLA
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1|Ph+ase 2
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with known MSI-high disease
https://ClinicalTrials.gov/show/NCT03953235

Comments are closed.

Up ↑